The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE
Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO
Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPOView Video
Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant
Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plantView Video

Latest Share Chat

Pin to quick picksFaron Pharma Share News (FARN)

Share Price Information for Faron Pharma (FARN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 155.00
Bid: 150.00
Ask: 160.00
Change: 5.00 (3.33%)
Spread: 10.00 (6.667%)
Open: 150.00
High: 155.00
Low: 155.00
Prev. Close: 150.00
FARN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Belluscura to raise GBP5 million; React buys

Thu, 12th May 2022 19:45

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

----------

Syncona Ltd - investor in healthcare companies - portfolio company, Autolus Therapeutics PLC to present data at European Hematology Association's Congress on June 9-12. Data includes positive early safety and efficacy data from AUTO4 in T cell lymphoma, and promising early data in AUTO1/22 programme in paediatric acute lymphoblastic leukaemia, as well as AUTO1 early safety and efficacy for relapsed/refractory primary central nervous system lymphoma.

----------

Faron Pharmaceuticals Ltd - Turku, Finland-based clinical stage biopharmaceutical company - Will present data on the potential of bexmarilimab in combination with standard of care for blood cancers at the European Hematology Association's Congress. Bexmarilimab is its wholly-owned novel precision cancer immunotherapy. It targets the Clever-1 receptor, which is associated with tumour-associated macrophages. "High Clever-1 expression is associated with poor survival in certain blood cancer patients and bexmarilimab provides a novel treatment approach for these patients, downregulating Clever-1 expression and igniting an effective immune response. We look forward to the imminent start of our hematology cancer clinical trial program to further explore these promising findings," says Chief Medical Officer Marie-Louise Fjallskog.

----------

Verici Dx PLC - Tennessee-based developer of clinical diagnostics for organ transplants - Results blinded, international, multi-centre validation study for Tuteva blood test showed significantly higher Positive Predictive Value for Tuteva than currently available kidney transplant blood tests. "The results reflect the wide clinical applicability of the test for comprehensive commercial adoption in a real-world setting," Verici says.

----------

Water Intelligence PLC - London-based leak detection services - Reacquires franchise in central Texas held within American Leak Detection subsidiary for USD750,000 cash, building upon acquisition of Forth Worth, Texas franchise in January. "The group is executing this regional hub model across the United States with its more than 150 corporate and franchise locations," the company says.

----------

Graft Polymer (UK) PLC - Slovenia-based polymer modification and drug delivery systems -Is granted Hazard Analysis & Critical Control Point certificate for its R&D facility in Slovenia for GraftBio division. "The HACCP certificate will allow us to create a strong reputation in the B2C market as a manufacturer of quality and safe food supplements, selling direct to consumers over time - a more lucrative revenue stream," says Chief Executive Officer Victor Bolduev.

----------

React Group PLC - South Derbyshire, England-based cleaning, hygiene and decontamination firm - Completes acquisition of window, gutter and cladding business LaddersFree Ltd for up to GBP8.5 million. GBP4.7 million is paid in cash, with GBP1.0 million in 83.3 million new ordinary shares at 1.2 pence each. Deferred consideration of GBP1.5 million to be paid in instalments. The acquired company has a "consistent track record of organic revenue growth and profitability", React says, and will broaden its customer base, reducing dependence on reactive and ad hoc work.

----------

AEX Gold Inc - Greenland-focused gold miner - Acquires mineral exploration licences No. 2020-41 and 2021-11 covering areas in south Greenland from Orano Group for no upfront consideration but a royalty on future production. The acquisition means AEX will be the largest licence holder in region, and the third-largest in Greenland, after Anglo American PLC and Greenfield Exploration. "We are excited to be substantially increasing our exposure to strategic metals and rare earth elements across Greenland. Greenland has the potential to become a crucial supplier of these vital minerals to the Western world, and AEX intends to be a key player in this," says Chief Executive Officer Eldur Olafsson.

----------

Puma VCT 12 PLC - venture capital trust managed by Puma Investments - Announces Sunlight Education Nucleus Ltd has been acquired, in which it invested GBP2.4 million in 2017. Exit represents 3.2 times return on its equity investment.

----------

Avation PLC - Singapore-based passenger aircraft leasing company - Completes second sale of series of ex-Virgin Australia Airlines ATR72-600s to Aegean Airlines for unspecified amount. Executive Chair Jeff Chatfield says: "Avation continues to reduce its few remaining unutilised aircraft in the fleet. We anticipate zero unutilised aircraft by the end of the calendar year 2022. Sales of unutilised aircraft provide capital to rebuild in a post-pandemic recovery phase."

----------

Belluscura PLC -London-based medical device developer - Will raise GBP5 million in accelerated bookbuild via placing of new shares. Proceeds will be used to fund the purchase of raw material inventory and non-recurring costs of manufacturing and engineering, in relation to its manufacturing agreement with InnoMax Medical Technology Ltd. Dowgate Capital Ltd is acting as sole placing agent, bookrunner and broker, with SPARK Advisory Partners Ltd acting as nominated adviser.

----------

Circle Property PLC - London-based buyer, developer and manager of regional office assets in UK - Has exchanged contracts for the sale of 720 Aztec West in Bristol to Maybrook Properties Ltd. Sale price of GBP2.5 million is a 77% increase on the valuation of GBP1.4 million at the end of March last year.

----------

Clontarf Energy PLC - Dublin-headquartered oil & gas exploration and production company focused on South America and Africa - Updates on drilling for Sasanof-1 exploration well. Says Valaris MS-1 rig is anchored in Dampier outer harbour, scheduled to commence tow to Sasanof-1 location on Monday. The operator Western Gas' drilling operations dteam are deployed to field and with now onboard MS-1 rig and undertake pre-mobilisation checks. Support vessels started operations on time on Monday. Drilling operations are expected to start on May 24. Has 10% working interest in Sasanof.

----------

Molten Ventures PLC - London-based venture capital firm focused on technology companies - Says portfolio company Aiven, a Finnish software company, closes externally-led series D funding round, raising USD210 million. Valuation of Aiven now USD3 billion, a "significant uplift on earlier rounds". Molten holds interest through Earlybird Partnership. Says carrying value of its holding in Aiven will be finalised as part of its final results on June 13.

----------

Mercia Asset Management PLC - regionally focused specialist asset manager – Says Knowledge-Intensive and annual Enterprise Investment Scheme funds raise total of around GBP20 million in new capital over past year.

----------

Kefi Gold & Copper PLC - Cyprus-based gold and copper exploration and development company with projects in Ethiopia and Saudi Arabia - Says progress in Ethiopia remains on track over past month, and multi-party project financing is developing. Expects to sign umbrella financing agreement this quarter, with full construction to commence from October, at the end of the current wet season. "KEFI has been able to pivot onto a much more positive direction since December 2021 due to geopolitics, regulatory changes and exploration results. We now have three advanced projects in two countries that are now overtly pro-development - a more positive and less risky position than KEFI has confronted for many years," says Executive Chair Harry Anagnostaras-Adams.

----------

European Metals Holdings Ltd - mineral exploration and development company focused on Cinovec lithium-tin project in Czech Republic - Accepted to trade on US based OTCQX Best Market, under the codes "EMHXY", "ERPNF" and "EMHLF" from Thursday. "Trading on the OTCQX comes at a pivotal time for investors seeking to leverage the transition away from fossil fuels, with the European Union offering significant funding to accelerate change and adoption rates of electric vehicles in the region continuing to climb," says Executive Chair Keith Coughlan.

----------

Future Metals NL - Perth-based platinum exploration company - Reports wide PGM assay results from drillhole samples at 100%-owned Panton PGM Project in northern Western Australia. Highlights include 60.5 metres at 1.24 grams per tonne palladium equivalent from 0 metres. "All drill hole results returned to date have confirmed significant intercepts of mineralisation, demonstrating the strong continuity of the Panton orebody along its current 3.5km strike, and the lateral extent of mineralisation sitting outside of the chromite reefs," says Chief Executive Officer & Managing Director Jardee Kininmonth. Is targeting new mineral resource estimate release in the coming weeks.

----------

Destiny Pharma PLC - Brighton-based clinical phase biotechnology company - Says data previously reported for c. difficile infection model study is accepted for presentation at Anaerobe 2022 Conference in Seattle. Data is on the ability of non-toxigenic strain M3 to colonise the gut following antibiotics. "The relevance and impact of this study cannot be underestimated as it indicates that the clinical use of fidaxomicin to treat CDI is unlikely to affect the ability of Destiny's late-stage asset, NTCD-M3, to colonise the gut and prevent recurrence of CDI," explains Chief Scientific Officer Bill Love.

----------

Mattioli Woods PLC - Leicester, England-based asset manager - Says subsidiary Ludlow Wealth Management Group Ltd has acquired Ferguson Financial Management Ltd for an initial GBP600,000 and potential further consideration of up to GBP600,000 million dependent on the attainment of performance targets in the year after completion.

----------

Capital Metals PLC - developing eastern minerals project in Sri Lanka - Says study for project demonstrates "exceptional economics" resulting in a high margin operation, enabling a short payback period. Says the long-term price assumptions used are below current prices suggesting "even more attractive economics are feasible". Further, it says the study does not take into account any potential resource extensions, which would enable the expansion of mine life and throughput, providing even further upside.

----------

HeiQ PLC - Zurich-based materials developer - Will pay deferred considerations relating to acquisitions of RAS AG and Life Material Technologies Ltd. Will pay EUR2.6 million to RAS based on its annual performance through ordinary shares of 30 pence each in HeiQ capital. Will pay USD2.8 million to Life, settled half in cash and half in new ordinary shares. Total new shares allotted for the transactions are 3.5 million.

----------

By Elizabeth Winter; elizabethwinter@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
13 Mar 2024 11:52

Faron Pharmaceuticals reports year of clinical progress

(Sharecast News) - Clinical-stage biopharmaceutical company Faron Pharmaceuticals reported a year of strong progress on Wednesday, with significant overall response rates seen in both previously hypomethylating agent (HMA)-failed and higher-risk myelodysplastic syndrome (MDS) patient populations in the phase one part of the BEXMAB study.

Read more
6 Mar 2024 16:06

UK earnings, trading statements calendar - next 7 days

Thursday 7 March 
Admiral Group PLCFull Year Results
Aviva PLCFull Year Results
Beazley PLCFull Year Results
Brooks Macdonald Group PLCHalf Year Results
Coats Group PLCFull Year Results
Darktrace PLCHalf Year Results
Elementis PLCFull Year Results
Entain PLCFull Year Results
Funding Circle Holdings PLCFull Year Results
Harbour Energy PLCFull Year Results
ITV PLCFull Year Results
Kier Group PLCFull Year Results
Melrose Industries PLCFull Year Results
Nexus Infrastructure PLCFull Year Results
PageGroup PLCFull Year Results
Physiomics PLCHalf Year Results
Rentokil Initial PLCFull Year Results
Robert Walters PLCFull Year Results
Spirax-Sarco Engineering PLCFull Year Results
TT Electronics PLCFull Year Results
Tyman PLCFull Year Results
Friday 8 March 
Informa PLCFull Year Results
Just Group PLCFull Year Results
LMS Capital PLCFull Year Results
Stelrad Group PLCFull Year Results
Monday 11 March 
HgCapital Trust PLCFull Year Results
Mincon Group PLCFull Year Results
MTI Wireless Edge LtdFull Year Results
Tuesday 12 March 
BATM Advanced Communications LtdFull Year Results
Costain Group PLCFull Year Results
Domino's Pizza Group PLCFull Year Results
Fonix Mobile PLCHalf Year Results
Foresight Solar Fund LtdFull Year Results
Genuit PLCFull Year Results
H&T Group PLCFull Year Results
Hill & Smith PLCFull Year Results
MaxCyte IncFull Year Results
Persimmon PLCFull Year Results
Synthomer PLCFull Year Results
Target Healthcare REIT PLCHalf Year Results
TI Fluid Systems PLCFull Year Results
TP ICAP Group PLCFull Year Results
Wednesday 13 March 
4imprint Group PLCFull Year Results
Advanced Medical Solutions Group PLCFull Year Results
Balfour Beatty PLCFull Year Results
Centaur Media PLCFull Year Results
Faron Pharmaceuticals LtdFull Year Results
Ferrexpo PLCFull Year Results
Gym Group PLCFull Year Results
Hochschild Mining PLCFull Year Results
IP Group PLCFull Year Results
Keywords Studios PLCFull Year Results
Kin & Carta PLCHalf Year Results
Metro Bank Holdings PLCFull Year Results
Nexteq PLCFull Year Results
PensionBee Group PLCFull Year Results
Public Policy Holding Co IncFull Year Results
Seraphim Space Investment Trust PLCHalf Year Results
Supermarket Income REIT PLCHalf Year Results
Trainline PLCTrading Statement
Vaalco Energy IncFull Year Results
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.

Read more
4 Mar 2024 19:59

TRADING UPDATES: Beowulf raises funds for Kallak iron ore project

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Read more
4 Mar 2024 10:40

Faron Pharmaceuticals shores up cash with EUR 3.2m convertible loans

(Sharecast News) - Faron Pharmaceuticals announced on Monday that it has successfully secured binding commitments for convertible loans totalling €3.2m from a select group of existing shareholders.

Read more
27 Feb 2024 21:12

TRADING UPDATES: Armadale Capital eyes Mahenge project financing

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
22 Feb 2024 17:36

EARNINGS AND TRADING: Astra closes Gracell buy, Amicorp "on track"

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Wednesday and Thursday and not separately reported by Alliance News:

Read more
22 Feb 2024 14:26

UK earnings, trading statements calendar - next 7 days

Friday 23 February 
City of London Investment Group PLCHalf Year Results
Irish Residential Properties REIT PLCFull Year Results
Standard Chartered PLCFull Year Results
Monday 26 February 
Base Resources LtdHalf Year Results
Bunzl PLCFull Year Results
EnSilica PLCHalf Year Results
Kosmos Energy LtdFull Year Results
Made Tech Group PLCHalf Year Results
Tristel PLCHalf Year Results
Tuesday 27 February 
abrdn Equity Income Trust PLCFull Year Results
abrdn PLCFull Year Results
Croda International PLCFull Year Results
Kitwave Group PLCFull Year Results
McBride PLCHalf Year Results
PCI-PAL PLCHalf Year Results
Smith & Nephew PLCFull Year Results
Synectics PLCFull Year Results
Uniphar PLCFull Year Results
Unite Group PLCFull Year Results
Wednesday 28 February 
AB Dynamics PLCTrading Statement
ASA International Group PLCTrading Statement
Aston Martin Lagonda Global Holdings PLCFull Year Results
Avingtrans PLCHalf Year Results
Bluefield Solar Income Fund LtdHalf Year Results
Derwent London PLCFull Year Results
Glenveagh Properties PLCFull Year Results
Grit Real Estate Income Group LtdHalf Year Results
Harmony Energy Income Trust PLCFull Year Results
Hutchmed China LtdFull Year Results
International Personal Finance PLCFull Year Results
Just Eat Takeaway.com NVFull Year Results
Primary Health Properties PLCFull Year Results
Reckitt Benckiser Group PLCFull Year Results
Renewables Infrastructure Group LtdFull Year Results
RHI Magnesita NVFull Year Results
St James's Place PLCFull Year Results
Taylor Wimpey PLCFull Year Results
Thursday 29 February 
Cairn Homes PLCFull Year Results
CVS Group PLCFull Year Results
Drax Group PLCFull Year Results
Faron Pharmaceuticals LtdFull Year Results
Haleon PLCFull Year Results
Hammerson PLCFull Year Results
Howden Joinery Group PLCFull Year Results
Hunting PLCFull Year Results
International Biotechnology Trust PLCFull Year Results
London Stock Exchange Group PLCFull Year Results
Macfarlane Group PLCFull Year Results
Man Group PLCFull Year Results
Mobico Group PLCFull Year Results
Nexus Infrastructure PLCFull Year Results
Ocado Group PLCFull Year Results
PPHE Hotel Group LtdFull Year Results
Schroder Oriental Income Fund LtdFull Year Results
Schroders PLCFull Year Results
Serco Group PLCFull Year Results
Shaftesbury Capital PLCFull Year Results
Spectris PLCFull Year Results
Spire Healthcare Group PLCFull Year Results
Vesuvius PLCFull Year Results
Weir Group PLCFull Year Results
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
19 Feb 2024 11:23

Faron discloses events of default on debt obligations to lender

(Alliance News) - Faron Pharmaceuticals Ltd shares fell on Monday, after it said it is in breach of several undertakings agreed in a secured debt deal with lender IPF Fund II SCA, SICAV-FIAR.

Read more
25 Jan 2024 20:09

TRADING UPDATES: Microsaic completes acquisition; Narf revenue soars

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
9 Jan 2024 12:36

Faron launches second phase of leukaemia treatment trial

(Sharecast News) - Faron Pharmaceuticals has initiated phase two of the BEXMAB trial, it announced on Tuesday, marking a significant milestone in its cancer treatment development programme.

Read more
9 Jan 2024 10:56

Faron says first patient dosed in phase two Bexmab trial for cancer

(Alliance News) - Faron Pharmaceuticals Ltd on Tuesday announced that the first patient has been dosed in phase 2 of its Bexmab trial.

Read more
11 Dec 2023 13:22

Faron unveils promising antibody study results

(Sharecast News) - Faron Pharmaceuticals unveiled promising phase one data from its BEXMAB study in myeloid malignancies during the 65th American Society of Hematology (ASH) annual meeting, it announced on Monday.

Read more
11 Dec 2023 12:01

Faron Pharmaceuticals hails positive results of cancer drug trial

(Alliance News) - Faron Pharmaceuticals Ltd on Monday said results from a probe of a cancer drug were promising.

Read more
7 Dec 2023 19:33

IN BRIEF: Faron Pharma celebrates publication of bexmarilimab results

Faron Pharmaceuticals Ltd - Finland-based clinical-stage biopharmaceutical company - Says that results from its Phase 1/2 MATINS trial of bexmarilimab have been published in Cell Reports Medicine, an open-access journal. According to the trial, bexmarilimab monotherapy shows efficacy in achieving disease control and prolonged survival in late-stage metastatic solid tumours. It also showed that CLEVER-1 targeting is safe and well-tolerated with no serious adverse effects, and that bexmarilimab induced macrophage activation and increased IFNy signalling in patients who achieved disease control and prolonged survival.

Read more
7 Dec 2023 11:01

Faron publishes cancer immunotherapy study findings

(Sharecast News) - Faron Pharmaceuticals announced the publication of the comprehensive findings from the groundbreaking phase one and two 'MATINS' trial of bexmarilimab on Thursday - its humanised monoclonal anti-CLEVER-1 antibody aimed at transforming the landscape of anticancer immunotherapies.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.